@article{00c02383a412455e9d8285c85abd8ea2,
title = "ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4",
abstract = "Kr{\"u}ppel-like factor 4 (KLF4) is an important transcription factor implicated in a variety of essential cellular processes. Aberrant KLF4 expression is closely related to tumourigenesis and tumour progression. The rapid turnover of the KLF4 protein indicates an important role for the posttranslational modifications (PTMs) of KLF4. To date, E3 ligases mediating KLF4 ubiquitination have been widely reported, yet the deubiquitinating mechanism of KLF4 remains largely unknown. We screened a library of 65 deubiquitinating enzymes and identified ATXN3 as a deubiquitinating enzyme of KLF4. Subsequent immunoprecipitation assays confirmed that ATXN3 bound to KLF4, mediating the deubiquitination and stabilization of KLF4 protein levels. Furthermore, we demonstrated that ATXN3 promoted breast cancer cell metastasis via KLF4 in vitro and in vivo. Finally, the protein expression analysis of human breast cancer specimens demonstrated that ATXN3 significantly correlated with KLF4. High ATXN3/KLF4 expression was associated with a poor prognosis in breast cancer patients. Collectively, we identified ATXN3 as a novel deubiquitinating enzyme of KLF4, providing a new explanation for breast cancer metastasis, and proposed ATXN3 as a potential target for breast cancer metastasis treatment.",
keywords = "ATXN3, Breast cancer, Deubiquitinating enzyme, KLF4, Metastasis",
author = "Haojing Zou and Hongyan Chen and Zhuan Zhou and Yong Wan and Zhihua Liu",
note = "Funding Information: The study was supported by the National Science Foundation of China ( 81420108025 , 81773134 ), the Chinese Academy of Medical Sciences Initiative for Innovative Medicine ( 2017-I2M-3-004 , 2016-I2M-1-001 ), the Sanming Project of Medicine in Shenzhen ( SZSM201812062 ), and bridging funds from the University of Pittsburgh School of Medicine . We thank Dr. Nianhong Chen for his efforts in deubiquitinating enzyme screening. We thank Dr. Aiping Luo for her support in KLF4 protein and breast cancer cell handling. We also thank Drs. Mingjing He and Jing Luo for their assistance in the ubiquitination and mapping assays. Funding Information: The study was supported by the National Science Foundation of China (81420108025, 81773134), the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2017-I2M-3-004, 2016-I2M-1-001), the Sanming Project of Medicine in Shenzhen (SZSM201812062), and bridging funds from the University of Pittsburgh School of Medicine. We thank Dr. Nianhong Chen for his efforts in deubiquitinating enzyme screening. We thank Dr. Aiping Luo for her support in KLF4 protein and breast cancer cell handling. We also thank Drs. Mingjing He and Jing Luo for their assistance in the ubiquitination and mapping assays. Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2019",
month = dec,
day = "28",
doi = "10.1016/j.canlet.2019.09.012",
language = "English (US)",
volume = "467",
pages = "19--28",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
}